RESUMEN
OBJECTIVE: We evaluated the efficacy and the safety parameters for Greenlight(®) laser to vaporise myoma. MATERIALS AND METHODS: We studied 6 utero after hysterectomies for myoma and used the Greenlight(®) laser with different level of power and duration on myoma and normal myometer. We compared the tissue effect with the monopolar and bipolar resection. We studied the tissue effect by histological exam. RESULTS: The Greenlight(®) laser is able to vaporize myoma with a low side effect on normal myometer of 85µm (199µm with bipolar and 254µm with monopolar). CONCLUSION: The laser Greenlight(®) is efficient to vaporize myoma in vitro and presents some safety parameter. This study could lead to a clinical prospective study to demonstrate its ability to treat symptomatic myoma.
Asunto(s)
Terapia por Láser/efectos adversos , Leiomioma/cirugía , Neoplasias Uterinas/cirugía , Adulto , Endometrio/patología , Femenino , Humanos , Histerectomía/efectos adversos , Histerectomía/métodos , Leiomioma/patología , Persona de Mediana Edad , Órganos en Riesgo/patología , Complicaciones Posoperatorias/etiología , Difusión Térmica , Resultado del Tratamiento , Neoplasias Uterinas/patologíaRESUMEN
Diabetic mastopathy is an uncommon benign entity occurring in young women with type 1 diabetes. Its clinical and radiological signs are not specific and often mimic a breast carcinoma. However, the benign nature of this lesion is easily recognized on histological examination, visualizing dense keloid-like fibrosis, lymphocytic lobulitis and ductitis with lymphocytic perivascular inflammation, with or without epithelioid-like fibroblasts. Surgery can generally be avoided. The evolution of this entity is characterized by the risk of local growth, bilateralisation or recurrence after surgical treatment. We present a case in which the core biopsy allowed the diagnosis of a diabetic mastopathy and we discuss its clinical, diagnostic, pathological and therapeutic particularities.
Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Enfermedad Fibroquística de la Mama/etiología , Enfermedad Fibroquística de la Mama/patología , Adulto , Diagnóstico Diferencial , Femenino , Enfermedad Fibroquística de la Mama/diagnóstico por imagen , Enfermedad Fibroquística de la Mama/terapia , Humanos , Radiografía , RecurrenciaRESUMEN
AIMS: To analyse the effects of the preoperative targeted molecular therapy (cetuximab (cetu) or bevacizumab (beva)) on non-tumorous liver parenchyma, and the clinical and biological outcome after liver resection for colorectal liver metastases (CLM). METHODS: Between January 2005 and December 2007, 36 patients receiving preoperatively cetu (n = 15) or beva (n = 21) were, respectively, matched to a control group of patients who did not receive targeted molecular therapy. They were matched on the basis of age, gender, body mass index, extent of hepatectomy, and type and number of neoadjuvant chemotherapy. Liver function tests, postoperative outcome and histopathology of the resected liver were compared. RESULTS: There was no mortality. Postoperative morbidity and perioperative bleeding rates were similar in both groups. In the beva group, liver function tests showed higher serum bilirubin level on postoperative day (POD) 1 (p = 0.001) and POD 3 (p = 0.01), higher serum aspartate aminotransferase on POD 1 (p = 0.004), and lower prothrombin time on POD 5 (p = 0.02). In both groups, cetu and beva, the postoperative peaks of gamma-glutamyl transpeptidase and alkaline phosphatase were statistically higher than in the control groups. Interestingly, the prevalence of sinusoidal injury and fibrosis was lower in patients receiving cetu (p = 0.04), while the prevalence of steatohepatitis was lower in patients receiving beva (p = 0.04). CONCLUSION: The addition of beva or cetu to the neoadjuvant chemotherapy regimens does not appear to increase the morbidity rates after hepatectomy for CLM. The pathological examination did not show additional injury to the non-tumorous liver parenchyma.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Colorrectales/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Factores de Edad , Anciano , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bevacizumab , Índice de Masa Corporal , Estudios de Casos y Controles , Cetuximab , Distribución de Chi-Cuadrado , Femenino , Fluorouracilo/efectos adversos , Fluorouracilo/uso terapéutico , Hepatectomía , Humanos , Leucovorina/efectos adversos , Leucovorina/uso terapéutico , Pruebas de Función Hepática , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Compuestos Organoplatinos/efectos adversos , Compuestos Organoplatinos/uso terapéutico , Complicaciones Posoperatorias/epidemiología , Factores Sexuales , Estadísticas no ParamétricasRESUMEN
Pancreatic leiomyosarcomas are a rare neoplasm that accounts for 1/1000 of pancreatic cancers. In the literature, 23 cases of pancreatic leiomyosarcoma have been reported and the majority being diagnosed on autopsy. It has never been reported any radical curative surgery in presence of synchronous hepatic metastasis. We reported a case of a patient affected by a primitive pancreatic leiomyosarcoma with bilobar hepatic metastasis, who underwent distal splenopancreatectomy associated with the resection of multiple liver metastases.
Asunto(s)
Hepatectomía , Leiomiosarcoma/cirugía , Neoplasias Hepáticas/cirugía , Pancreatectomía , Neoplasias Pancreáticas/cirugía , Esplenectomía , Anciano , Ablación por Catéter/métodos , Femenino , Hepatectomía/métodos , Humanos , Leiomiosarcoma/secundario , Neoplasias Hepáticas/secundario , Pancreatectomía/métodos , Neoplasias Pancreáticas/patología , Esplenectomía/métodos , Resultado del TratamientoRESUMEN
INTRODUCTION: Castleman's disease is a rare orphan disease. The prevalence is estimated at less than 1/100 000. Respirologists may encounter this disease when its thoracic manifestations occur. CASE REPORT: The authors report two cases of Castleman's disease with two different thoracic involvements. The first patient was a 20-year-old man without a previous medical history. A chance chest X-ray revealed right basal opacity. A lung biopsy demonstrated giant lymph node polyclonal hyperplasia leading to the diagnosis of a thoracic form of Castleman's disease. Since the patient was completely symptom free, no treatment was proposed. The patient was stable after 10months of medical supervision. The second patient, a 34-year-old woman, had a medical history of myasthenia gravis, autoimmune thrombopenic purpura and haemolytic anaemia. Her general condition deteriorated and upper mediastinal enlargement was noted. A diagnosis of multicentric Castleman's disease was established by means of the biopsy of an axillary lymph node. As the symptoms persisted, she was treated by rituximab. The clinical response was dramatic. CONCLUSION: The authors call to mind the difficult diagnostic features and therapeutic strategies of Castleman's disease, a rare disease which may involve the thorax.